Cognition Therapeutics Inc. (NASDAQ: CGTX)
$1.96
+0.0400 ( +2.08% ) 62.3K
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
Market Data
Open
$1.96
Previous close
$1.92
Volume
62.3K
Market cap
$79.32M
Day range
$1.90 - $2.02
52 week range
$0.90 - $2.95
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
def | Proxies and info statements | 9 | Apr 26, 2024 |
ars | Annual reports | 1 | Apr 26, 2024 |
8-k | 8K-related | 15 | Mar 26, 2024 |
10-k | Annual reports | 99 | Mar 26, 2024 |
4 | Insider transactions | 1 | Mar 14, 2024 |
8-k | 8K-related | 17 | Mar 13, 2024 |
8-k | 8K-related | 14 | Mar 11, 2024 |
4 | Insider transactions | 2 | Feb 20, 2024 |
4 | Insider transactions | 2 | Feb 20, 2024 |
8-k | 8K-related | 15 | Feb 20, 2024 |